Privia Health Group (PRVA) Set to Announce Quarterly Earnings on Thursday

Privia Health Group (NASDAQ:PRVA) will be releasing its earnings data before the market opens on Thursday, August 8th. Analysts expect Privia Health Group to post earnings of $0.05 per share for the quarter. Privia Health Group has set its FY 2024 guidance at EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Privia Health Group (NASDAQ:PRVA) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.03). The business had revenue of $415.24 million during the quarter, compared to the consensus estimate of $435.07 million. Privia Health Group had a return on equity of 3.13% and a net margin of 1.11%. On average, analysts expect Privia Health Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Privia Health Group Price Performance

Shares of NASDAQ:PRVA opened at $19.29 on Wednesday. The business’s 50-day moving average is $18.04 and its 200-day moving average is $19.04. Privia Health Group has a 1 year low of $15.92 and a 1 year high of $27.59. The company has a market capitalization of $2.30 billion, a price-to-earnings ratio of 128.60, a P/E/G ratio of 3.38 and a beta of 0.78.

Insider Buying and Selling

In related news, Director Adam Boehler bought 277,565 shares of the company’s stock in a transaction on Tuesday, May 21st. The shares were purchased at an average cost of $16.17 per share, for a total transaction of $4,488,226.05. Following the completion of the purchase, the director now directly owns 5,488,701 shares in the company, valued at $88,752,295.17. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. In other Privia Health Group news, Director Thomas A. Mccarthy bought 10,000 shares of Privia Health Group stock in a transaction dated Thursday, May 23rd. The stock was purchased at an average price of $16.37 per share, for a total transaction of $163,700.00. Following the completion of the purchase, the director now directly owns 52,611 shares of the company’s stock, valued at $861,242.07. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Adam Boehler purchased 277,565 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The shares were acquired at an average price of $16.17 per share, for a total transaction of $4,488,226.05. Following the completion of the purchase, the director now directly owns 5,488,701 shares in the company, valued at approximately $88,752,295.17. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 293,235 shares of company stock worth $4,745,481 and sold 17,607 shares worth $314,813. 14.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

PRVA has been the topic of a number of research analyst reports. Citigroup assumed coverage on Privia Health Group in a report on Monday, April 22nd. They set a “buy” rating and a $25.00 price target on the stock. Stifel Nicolaus decreased their price target on shares of Privia Health Group from $28.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Truist Financial cut their price objective on shares of Privia Health Group from $28.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, May 15th. Canaccord Genuity Group decreased their target price on Privia Health Group from $37.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, May 10th. Finally, Robert W. Baird assumed coverage on Privia Health Group in a research note on Thursday, May 30th. They set an “outperform” rating and a $23.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Privia Health Group currently has an average rating of “Moderate Buy” and a consensus price target of $24.54.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.